ClinicalTrials.gg
Enrolling by invitationNCT05448768Updated Oct 22, 2026

Cognitive Effects and Potential Mechanisms of TBS in Subjects With MCI

An interventional study of TBS for Amyloid-positive MCI and TBS for Amyloid-negative MCI in Mild Cognitive Impairment, sponsored by Chang Gung Memorial Hospital. Enrolling by invitation at 1 site in Taiwan. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Chang Gung Memorial Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Cognitive Dysfunction by Chang Gung Memorial Hospital — 6 open to participants now, 6 under way, none of them phase 3. Cognitive Dysfunction · Chang Gung Memorial Hospital.

Planned enrollment
11th of 22
80 · median 80
Started
2022
with 1 other
No phase
14 of 26
5 open now
Registered
20th of 26
by date

Among the 26 studies in Cognitive Dysfunction by Chang Gung Memorial Hospital, this one is the 11th largest by planned enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2022, is one of 14 with no phase, and was the 20th registered.

Cognitive Dysfunction

3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.

Browse Cognitive Dysfunction studies →

Open to participants now

6 of the 26 studies in Cognitive Dysfunction by Chang Gung Memorial Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Cognitive Dysfunction by Chang Gung Memorial Hospital, or all of them as a file.
02

Study summary

This study aims to examine the effects and potential mechanisms of theta-burst stimulation (TBS) on cognitive function in individuals with mild cognitive impairment (MCI).

Read the detailed description

The investigators apply the NIA-AA criteria to subtype different endophenotypes of biomarker-defined MCI individuals. This is a prospective, open-label clinical trial, and combined functional neuroimaging study of 18F-FDG-PET to further explore the potential mechanisms. A total of 80 MCI patients will be consecutively recruited and be subjected to iTBS for 5 daily interventions per week for two consecutive weeks. Cognitive evaluation will be performed before and immediately after TBS intervention, and 8 weeks after TBS. Data on functional neuroimaging will be also collected before and after TBS protocol.

03

Conditions studied

  • Mild Cognitive Impairment

Keywords

  • Mild Cognitive Impairment
  • theta-burst stimulation
  • repetitive transcranial magnetic stimulation (rTMS)
04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects aged 50-90 year
  2. Subjects meet Petersen's criteria for mild cognitive impairment (Petersen, Smith et al. 1999)
  3. The CDR of MCI patients can be 0-0.5
  4. Amyloid PET should ever be performed

Exclusion criteria

Exclusion Criteria:

  1. Any subject has a definite diagnosis of epilepsy or history of seizure attack.
  2. Current or past history of neurological insults affecting brain structure or function like completed stroke, head injury or brain tumor.
  3. Any subject has clinically significant or unstable medical diseases including metabolic, renal,liver, lung or cardiovascular disorders including metabolic, renal, liver, lung or cardiovascular disorders.
  4. Any subject has current alcohol or other substances abuse and/ or dependence within the recent one year, or prolonged history of major psychiatric disorder like schizophrenia,bipolar disorder, and previously prolonged substances abuse.
  5. Any females who is pregnant or lactating.
  6. General MRI, TMS and/or PET exclusion criteria including subjects who had received brain aneurysm surgery, or implanted pacemaker, mechanical valves, cochlear implant or other metal devices/ objects that are not MR compatible in the body.

Withdrawal criteria

  1. Complications onset after intervention that affect efficacy and safety judgments.
  2. New onset or progression of disease that may affect outcomes.
  3. Use of other therapies or drugs during the intervention period to change cognitive functions.
  4. Any subjects who are recognized as high risk of adverse effects by principle investigator.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Amyloid-positive MCI

    The subjects will receive active stimulation of standard intermittent TBS (iTBS) protocol.

    Device: TBS for Amyloid-positive MCI

  • Active comparator
    Amyloid-negative MCI

    The subjects will receive active stimulation of standard intermittent TBS (iTBS) protocol.

    Device: TBS for Amyloid-negative MCI

Interventions

  • DeviceTBS for Amyloid-positive MCI

    The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.

  • DeviceTBS for Amyloid-negative MCI

    The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.

06

What researchers measure

Primary outcomes

  1. Mini-Mental State Examination ( MMSE )

    Change from baseline Mini-Mental State Examination total scores immediately after TBS intervention

    Time frame: Baseline and immediately after 2 weeks of TBS and 8-week follow-up after TBS

  2. Montreal Cognitive Assessment

    Change from baseline Montreal Cognitive Assessment total scores immediately after TBS intervention

    Time frame: Baseline and immediately after 2 weeks of TBS and 8-week follow-up after TBS

Secondary outcomes

  1. The standard uptake values changes of FDG-PET

    The standard uptake values (SUV) changes of cerebral glucose metabolism using 18F-FDG-PET

    Time frame: Before and immediately after TBS intervention

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Jun 2027, 57 months after the start.

Of 1,453 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's planned 57 months is above that.

Counting every sponsor, half of 1,522 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2022
First posted
Jul 7, 2022
StartActual
Sep 13, 2022
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05448768
Responsible party
Sponsor
First posted
Jul 7, 2022
Start date
Sep 13, 2022
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

KUAN YI WU
principal investigator · Chang Gung Memorial Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion